Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens

SETTING: National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.OBJECTIVE: To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and an injectable agent.DESIGN: Prospective cohort of pat...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of tuberculosis and lung disease 2021-08, Vol.25 (8), p.632-639
Main Authors: Smith, A. G. C., Gujabidze, M., Avaliani, T., Blumberg, H. M., Collins, J. M., Sabanadze, S., Bakuradze, T., Avaliani, Z., Kempker, R. R., Kipiani, M.
Format: Article
Language:English
Subjects:
Clinical outcomes
Empiric Regimen
Health services
Linezolid
Lung diseases
Meningitis
Mortality
Multidrug resistance
Multidrug resistant organisms
Multidrug-Resistant
Neurologic Outcomes
Patients
Tbm
Tuberculosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SETTING: National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.OBJECTIVE: To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and an injectable agent.DESIGN: Prospective cohort of patients aged ≥16 years initiating treatment for TBM at the NCTLD from January 2018 to December 2019. Treatment outcomes and neurologic disability at 1, 6 and 12 months after treatment initiation were assessed.RESULTS: Among 77 patients with median follow-up time of 363 days (IQR 269-374), 97% received a FQ, 62% an injectable agent, 44% linezolid and 39% a carbapenem. Fifty-seven patients (74%) successfully completed treatment, 2 (2.6%) had treatment failure, 6 (7.8%) died, and the remainder (12%) were lost to follow up. Among 11 patients treated for multidrug-resistant TBM, the median follow-up time was 467 days and one patient (8%) died. Regarding neurologic outcomes, 14/76 (18%) patients had Modified Rankin Scores of 0 at baseline, improving to 85% (56/66) and 94% (47/50) at 6 and 12 months, respectively.CONCLUSION: Intensified multidrug treatment regimens including a FQ and an injectable agent in all patients and newly implemented drugs in patients with multidrug-resistant TBM resulted in low mortality and favorable neurologic outcomes.
ISSN:1027-3719
1815-7920
DOI:10.5588/ijtld.21.0159